We found that knocking down YBX1 resulted in attenuated sorafenib resistance, increased apoptosis, and disrupted cell morphology in all three sorafenib-resistant HCC cell lines (Fig. 3o and Supplementary Fig. 2M). Here, YBX1 is linked to hepatocellular carcinoma.